Exposure‐Response Analyses of Upadacitinib Efficacy and Safety in Phase 2 and 3 Studies to Support Benefit‐Risk Assessment in Rheumatoid Arthritis

Clinical Pharmacology and Therapeutics - United States
doi 10.1002/cpt.1671

Related search